UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

AmerisourceBergen Corporation

(Exact name of registrant as specified in its charter)

Delaware		1-16671		23-3079390
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1300 Morris Drive Chesterbrook, PA		19087
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (610) 727-7000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 8.01. Other Events.

On April 4, 2011, AmerisourceBergen Corporation (the “Company”) issued a news release announcing that the Company has named David W. Neu, 53, as President of AmerisourceBergen Drug Corporation (“ABDC”), the Company’s largest operating unit, effective immediately. Mr. Neu has been with the Company for 29 years and was most recently Senior Vice President, Operations for ABDC. Mr. Neu will continue to report to Steven Collis, currently Executive Vice President and Chief Operating Officer, and recently named to succeed David Yost as Chief Executive Officer upon Mr. Yost’s retirement on July 1, 2011.

The news release issued on April 4, 2011 is filed as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 News Release, dated April 4, 2011, regarding the appointment of David W. Neu as President of AmerisourceBergen Drug Corporation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.